Search

Pharmaceutical technologies are commonly designed and validated under controlled assumptions about materials, processes, supply continuity, and patient use. Yet once products enter development, scale-up, manufacturing, distribution, and real-world use, they encounter variability that cannot be fully predicted or eliminated. Supply disruptions, raw-material shifts, equipment drift, environmental fluctuations, and heterogeneous patient behaviours can all disturb the intended relationship between product design and therapeutic performance. The prevailing pharmaceutical design paradigm has made important advances through quality-by-design, risk management, and process analytical technology. However, it often treats variability primarily as a deviation from a predefined optimum rather than as a persistent condition of system operation. This creates a risk that pharmaceutical technologies become highly optimised for expected conditions but brittle when exposed to unfamiliar combinations of supply, process, and patient-level stressors. This article proposes an original resilience-theoretic framework for pharmaceutical technology design. The framework argues that technologies should be designed not only to meet specifications under normal conditions, but also to absorb disturbance, adapt to changing conditions, maintain acceptable performance, and degrade gracefully when ideal operation is no longer possible. It therefore reframes resilience as a design objective rather than a post hoc recovery capability. The article contributes a conceptual structure for aligning pharmaceutical technology design with the realities of variability. It shows how resilience thinking can connect supply robustness, process adaptability, and patient-centred performance into a single design logic. Designing for resilience represents a shift from static robustness toward dynamic adaptability, offering a pathway to pharmaceutical technologies that remain reliable, usable, and therapeutically meaningful under changing conditions.

Pharmaceutical translation depends on coordinated movement across discovery, formulation, engineering, clinical development, regulatory assessment, and real-world adoption. Yet these domains are not organised around a single language, evidence standard, or professional logic. Scientists, engineers, clinicians, and regulators often evaluate the same innovation through different assumptions about value, risk, feasibility, and acceptable uncertainty. A critical but under-recognised cause of translational delay is the absence of shared artefacts that can carry meaning across these disciplinary worlds. When a formulation concept, manufacturing constraint, clinical use condition, or regulatory concern is represented only in the vocabulary of one group, it becomes difficult for others to interpret its implications. This produces misaligned specifications, late-stage redesign, evidence fragmentation, and avoidable regulatory friction. This article introduces boundary object theory as a translational lens for pharmaceutical innovation. Boundary objects are artefacts that remain stable enough to support shared work while remaining flexible enough to be interpreted by different professional communities. Applied to pharmaceutical development, they include target product profiles, critical quality attributes, design space diagrams, pharmacokinetic–pharmacodynamic models, control strategies, clinical administration guides, and regulatory summaries. The article constructs an original translational framework that identifies how boundary objects can be designed, evaluated, and positioned across formulation science, process engineering, clinical practice, and regulatory assessment. It argues that pharmaceutical translation should not be understood only as the transfer of data or documentation, but as the progressive alignment of meanings, expectations, and decisions through structured artefacts. The proposed framework positions boundary object design as a practical intervention for improving translational continuity. By making assumptions, sensitivities, use conditions, uncertainties, and decision consequences visible across disciplines, boundary objects can reduce communication failure and support more coherent innovation pathways. The article calls for deliberate integration of boundary object thinking into pharmaceutical development programmes, regulatory communication, and translational training.